• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

降压药物引起的醛固酮与动脉僵硬度降低的相关性:J-CORE 研究。

Association between aldosterone induced by antihypertensive medication and arterial stiffness reduction: the J-CORE study.

机构信息

Division of Cardiovascular Medicine, Department of Medicine, Jichi Medical University School of Medicine, 3311-1 Yakushiji, Shimotsuke, Tochigi 329-0498, Japan.

出版信息

Atherosclerosis. 2011 Mar;215(1):184-8. doi: 10.1016/j.atherosclerosis.2010.12.022. Epub 2010 Dec 30.

DOI:10.1016/j.atherosclerosis.2010.12.022
PMID:21241987
Abstract

OBJECTIVE

Excess aldosterone has a detrimental effect on large artery stiffness. We aimed to investigate the association of the change in plasma aldosterone concentration (PAC) by antihypertensive medication with the change in aortic pulse wave velocity (aPWV).

METHODS

We conducted a prospective, randomized, open-label, blinded end-point study in 207 hypertensive patients. Patients received olmesartan monotherapy for 12 weeks, followed by add-on use of hydrochlorothiazide (HCTZ; n=104) or azelnidipine (n=103) for 24 weeks after randomization. The aPWV, which was determined by measuring the carotid to femoral PWV, and laboratory data were assessed at baseline and 24 weeks later.

RESULTS

PAC in the HCTZ group increased more than that in the azelnidipine group, while aPWV and mean arterial pressure in the azelnidipine group decreased more than those in the HCTZ group. In univariable analyses, the change in PAC was significantly and positively correlated with the change in aPWV in the total population (r=0.26, P<0.001) and the HCTZ group (r=0.28, P=0.004), but not in the azelnidipine group (r=0.17, P=0.09). In multivariable analyses, a positive association of the change in PAC with the change in aPWV was observed in the total population (standardized regression coefficient β=0.18, P<0.001) and the HCTZ group (β=0.23, P=0.004), independently of the changes in covariates, but not in the azelnidipine group (β=0.13, P=0.06).

CONCLUSION

The change in PAC was significantly and positively associated with the change in aPWV in patients treated with HCTZ. These findings may partly explain why thiazide diuretics have little effect on large artery stiffness.

摘要

目的

过量的醛固酮对大动脉僵硬度有不利影响。我们旨在研究降压药物治疗后血浆醛固酮浓度(PAC)的变化与主动脉脉搏波速度(aPWV)的变化之间的关系。

方法

我们在 207 名高血压患者中进行了一项前瞻性、随机、开放标签、盲终点研究。患者接受奥美沙坦单药治疗 12 周,随后在随机分组后 24 周加用氢氯噻嗪(HCTZ;n=104)或阿折地平(n=103)。通过测量颈动脉-股动脉脉搏波速度来确定 aPWV,并在基线和 24 周后评估实验室数据。

结果

HCTZ 组的 PAC 增加多于阿折地平组,而阿折地平组的 aPWV 和平均动脉压下降多于 HCTZ 组。在单变量分析中,总人群(r=0.26,P<0.001)和 HCTZ 组(r=0.28,P=0.004)中 PAC 的变化与 aPWV 的变化呈显著正相关,但在阿折地平组中无相关性(r=0.17,P=0.09)。在多变量分析中,总人群(标准化回归系数β=0.18,P<0.001)和 HCTZ 组(β=0.23,P=0.004)中 PAC 变化与 aPWV 变化呈正相关,与协变量变化独立,但在阿折地平组中无相关性(β=0.13,P=0.06)。

结论

在接受 HCTZ 治疗的患者中,PAC 的变化与 aPWV 的变化显著正相关。这些发现可能部分解释了噻嗪类利尿剂对大动脉僵硬度影响较小的原因。

相似文献

1
Association between aldosterone induced by antihypertensive medication and arterial stiffness reduction: the J-CORE study.降压药物引起的醛固酮与动脉僵硬度降低的相关性:J-CORE 研究。
Atherosclerosis. 2011 Mar;215(1):184-8. doi: 10.1016/j.atherosclerosis.2010.12.022. Epub 2010 Dec 30.
2
Association of changes in ambulatory arterial stiffness index and pulse wave velocity during antihypertensive treatment: the J-CORE study.降压治疗期间动态动脉硬化指数和脉搏波速度变化的相关性:J-CORE 研究。
Am J Hypertens. 2012 Aug;25(8):862-8. doi: 10.1038/ajh.2012.64. Epub 2012 May 31.
3
Differential effects between a calcium channel blocker and a diuretic when used in combination with angiotensin II receptor blocker on central aortic pressure in hypertensive patients.钙通道阻滞剂和利尿剂与血管紧张素II受体阻滞剂联合使用时对高血压患者中心主动脉压的不同影响。
Hypertension. 2009 Oct;54(4):716-23. doi: 10.1161/HYPERTENSIONAHA.109.131466. Epub 2009 Aug 10.
4
Combined effect of angiotensin II receptor blocker and either a calcium channel blocker or diuretic on day-by-day variability of home blood pressure: the Japan Combined Treatment With Olmesartan and a Calcium-Channel Blocker Versus Olmesartan and Diuretics Randomized Efficacy Study.血管紧张素 II 受体阻滞剂联合钙通道阻滞剂或利尿剂对家庭血压日内变异性的影响:奥美沙坦与钙通道阻滞剂联合治疗与奥美沙坦和利尿剂随机疗效研究。
Hypertension. 2012 Jun;59(6):1132-8. doi: 10.1161/HYPERTENSIONAHA.111.189217. Epub 2012 Apr 30.
5
Effects of combination therapy with olmesartan and azelnidipine on serum osteoprotegerin in patients with hypertension.奥美沙坦与阿折地平联合治疗对高血压患者血清护骨素的影响。
J Cardiovasc Pharmacol Ther. 2014 May;19(3):304-9. doi: 10.1177/1074248413511692. Epub 2013 Nov 28.
6
Angiotensin-II receptor antagonist combined with calcium channel blocker or diuretic for essential hypertension.血管紧张素 II 受体拮抗剂联合钙通道阻滞剂或利尿剂治疗原发性高血压。
Hypertens Res. 2009 Nov;32(11):962-8. doi: 10.1038/hr.2009.133. Epub 2009 Aug 21.
7
Additive antioxidative effects of azelnidipine on angiotensin receptor blocker olmesartan treatment for type 2 diabetic patients with albuminuria.阿折地平对血管紧张素受体拮抗剂奥美沙坦治疗伴蛋白尿的 2 型糖尿病患者的附加抗氧化作用。
Hypertens Res. 2011 Aug;34(8):935-41. doi: 10.1038/hr.2011.67. Epub 2011 Jun 9.
8
Kidney-protective effects of azelnidipine versus a diuretic in combination with olmesartan in hypertensive patients with diabetes and albuminuria: a randomized study.在伴有蛋白尿的糖尿病高血压患者中,阿折地平对比利尿剂联合奥美沙坦的护肾作用:一项随机研究。
Nephrol Dial Transplant. 2013 Jul;28(7):1802-10. doi: 10.1093/ndt/gft034. Epub 2013 Mar 27.
9
Comparison of combination therapy of olmesartan plus azelnidipine or hydrochlorothiazide on renal and vascular damage in SHR/NDmcr-cp rats.奥美沙坦联合阿折地平或氢氯噻嗪治疗对 SHR/NDmcr-cp 大鼠肾脏和血管损伤的比较。
Kidney Blood Press Res. 2011;34(2):87-96. doi: 10.1159/000323535. Epub 2011 Jan 27.
10
Effects of manidipine/delapril versus olmesartan/hydrochlorothiazide combination therapy in elderly hypertensive patients with type 2 diabetes mellitus.马尼地平/地拉普利与奥美沙坦/氢氯噻嗪联合治疗对老年2型糖尿病高血压患者的疗效
Hypertens Res. 2008 Jan;31(1):43-50. doi: 10.1291/hypres.31.43.

引用本文的文献

1
Mineralocorticoid receptor antagonist treatment improved arterial stiffness in patients with primary aldosteronism: a cohort study compared with adrenalectomy.盐皮质激素受体拮抗剂治疗改善原发性醛固酮增多症患者的动脉僵硬度:一项与肾上腺切除术比较的队列研究
Ther Adv Chronic Dis. 2023 Jan 16;14:20406223221143233. doi: 10.1177/20406223221143233. eCollection 2023.
2
Does Excess Tissue Sodium Storage Regulate Blood Pressure?过多的组织钠储存会调节血压吗?
Curr Hypertens Rep. 2022 May;24(5):115-122. doi: 10.1007/s11906-022-01180-x. Epub 2022 Feb 22.
3
Effects of Various Antihypertensive Drugs on Arterial Stiffness and Wave Reflections.
各类抗高血压药物对动脉僵硬度和波反射的影响。
Pulse (Basel). 2013 Oct;1(2):97-107. doi: 10.1159/000354108. Epub 2013 Sep 10.
4
Impact of Antihypertensive Agents on Central Systolic Blood Pressure and Augmentation Index: A Meta-Analysis.抗高血压药物对中心收缩压和增强指数的影响:一项荟萃分析。
Am J Hypertens. 2016 Apr;29(4):448-57. doi: 10.1093/ajh/hpv134. Epub 2015 Aug 19.
5
Reduction of plasma aldosterone and arterial stiffness in obese pre- and stage1 hypertensive subjects after aerobic exercise.有氧运动后肥胖前期和1期高血压受试者血浆醛固酮水平降低及动脉僵硬度改善
J Hum Hypertens. 2015 Jan;29(1):53-7. doi: 10.1038/jhh.2014.33. Epub 2014 May 1.
6
Validation of the new Complior sensor to record pressure signals non-invasively.新型Complior传感器用于无创记录压力信号的验证。
J Clin Monit Comput. 2013 Dec;27(6):613-9. doi: 10.1007/s10877-013-9477-y. Epub 2013 May 17.
7
Genetic variation in CYP17A1 is associated with arterial stiffness in diabetic subjects.CYP17A1基因变异与糖尿病患者的动脉僵硬度相关。
Exp Diabetes Res. 2012;2012:827172. doi: 10.1155/2012/827172. Epub 2012 Oct 23.
8
Albuminuria-reducing effect of angiotensin II receptor blocker plus hydrochlorothiazide combination therapy in renal transplant recipients.血管紧张素II受体阻滞剂联合氢氯噻嗪治疗对肾移植受者蛋白尿的降低作用
Exp Ther Med. 2012 Jul;4(1):105-108. doi: 10.3892/etm.2012.542. Epub 2012 Apr 11.